Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems.
about
Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA).Antibiotic strategies in the era of multidrug resistanceGlobal Dissemination of Carbapenemase-Producing Klebsiella pneumoniae: Epidemiology, Genetic Context, Treatment Options, and Detection MethodsBeyond Susceptible and Resistant, Part III: Treatment of Infections due to Gram-Negative Organisms Producing CarbapenemasesTigecycline Treatment for Carbapenem-Resistant Enterobacteriaceae Infections: A Systematic Review and Meta-AnalysisAntibiotic regimens for treatment of infections due to multidrug-resistant Gram-negative pathogens: An evidence-based literature reviewNew Insight on Epidemiology and Management of Bacterial Bloodstream Infection in Patients with Hematological MalignanciesWhat's new in multidrug-resistant pathogens in the ICU?Treatment Options for Carbapenem-Resistant Enterobacteriaceae InfectionsEmergence of KPC-producing Klebsiella pneumoniae ST512 isolated from cerebrospinal fluid of a child in Algeria.EUropean prospective cohort study on Enterobacteriaceae showing REsistance to CArbapenems (EURECA): a protocol of a European multicentre observational study.Antibiotic resistance: What is so special about multidrug-resistant Gram-negative bacteria?Clinical and laboratory considerations for the rapid detection of carbapenem-resistant Enterobacteriaceae.Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae.Extensively Drug-Resistant Klebsiella pneumoniae Causing Nosocomial Bloodstream Infections in China: Molecular Investigation of Antibiotic Resistance Determinants, Informing Therapy, and Clinical Outcomes.Expansion and evolution of a virulent, extensively drug-resistant (polymyxin B-resistant), QnrS1-, CTX-M-2-, and KPC-2-producing Klebsiella pneumoniae ST11 international high-risk clone.Carbapenemase-producing Klebsiella pneumoniae.Therapy of Infections due to Carbapenem-Resistant Gram-Negative PathogensAntibiotic-resistant gram-negative bacterial infections in patients with cancer.Doripenem MICs and ompK36 porin genotypes of sequence type 258, KPC-producing Klebsiella pneumoniae may predict responses to carbapenem-colistin combination therapy among patients with bacteremia.Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant Klebsiella pneumoniaeThree Dimensional Checkerboard Synergy Analysis of Colistin, Meropenem, Tigecycline against Multidrug-Resistant Clinical Klebsiella pneumonia IsolatesActivity of antimicrobial combinations against KPC-2-producing Klebsiella pneumoniae in a rat model and time-kill assay.Carbapenemase-producing Enterobacteriaceae.Outcomes and Risk Factors for Mortality among Patients Treated with Carbapenems for Klebsiella spp. Bacteremia.Characterization and Clinical Impact of Bloodstream Infection Caused by Carbapenemase-Producing Enterobacteriaceae in Seven Latin American Countries.Large Nosocomial Outbreak of Colistin-Resistant, Carbapenemase-Producing Klebsiella pneumoniae Traced to Clonal Expansion of an mgrB Deletion Mutant.Polymyxin B in Combination with Antimicrobials Lacking In Vitro Activity versus Polymyxin B in Monotherapy in Critically Ill Patients with Acinetobacter baumannii or Pseudomonas aeruginosa Infections.Carbapenemase-Producing Klebsiella pneumoniae, a Key Pathogen Set for Global Nosocomial DominanceNosocomial Outbreak of OXA-48-Producing Klebsiella pneumoniae in a Chinese Hospital: Clonal Transmission of ST147 and ST383Klebsiella pneumoniae bloodstream infection: epidemiology and impact of inappropriate empirical therapy.A prospective study of treatment of carbapenem-resistant Enterobacteriaceae infections and risk factors associated with outcome.Efficacy of Appropriate Antimicrobial Therapy on the Survival of Patients With Carbapenem Nonsusceptible Klebsiella Pneumoniae Infection: A Multicenter Study in Taiwan.Carbapenem-resistant Klebsiella pneumoniae in high-risk haematological patients: factors favouring spread, risk factors and outcome of carbapenem-resistant Klebsiella pneumoniae bacteremias.Phagocytosis and Killing of Carbapenem-Resistant ST258 Klebsiella pneumoniae by Human Neutrophils.Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocolAminoglycosides for Treatment of Bacteremia Due to Carbapenem-Resistant Klebsiella pneumoniaeBloodstream infections in the Intensive Care Unit.An Immunocompromised Child with Bloodstream Infection Caused by Two Escherichia coli Strains, One Harboring NDM-5 and the Other Harboring OXA-48-Like Carbapenemase.Combination Regimens for Treatment of Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections.
P2860
Q26739860-E670CD96-0BAD-45B2-9A8A-7F97DB311AACQ26744091-B2489C96-B22C-4E95-9D14-B1EB60914AF3Q26744583-1F5773AA-93E3-4F41-B2BA-06A2C4CFAB03Q26747580-8D30E106-5E04-46C5-8E26-0C29A49C6D3FQ26764796-02166527-67C4-4E6C-A6DB-E4CBF4A837BDQ26796605-A4C67259-1CA1-4AAB-9D23-2ED0F4BA7049Q26799580-DE13E0B0-141D-4A5D-8EE5-75EE9AB68827Q28071346-ADC908EB-57B5-4653-A981-8917B69695E2Q28082546-294B3C7B-15F6-496C-9A3D-FA38F6FC105CQ30372567-30EE5948-2ECD-448E-8966-E2788C8A0397Q33552772-093F7983-1C24-4337-B900-7E0D5C7014FEQ33555383-8A13B931-5E0B-461C-8618-C2B9297EF831Q33816207-B8A44801-DB95-4152-80D1-BEF7CD9DF05BQ33816251-E98B6C7E-3096-4A5D-A0F4-7B9240569D33Q33857498-C25A9A49-6E55-4164-B005-C0178028B6E8Q33899961-BDFDCA49-B9AD-4915-AA8D-EEC48D08FE3FQ34201937-489D0A37-D03B-4EA4-828A-9C00D6822517Q34303970-9F7795A2-1C47-4536-9B61-B81918E257DEQ34999880-BA12B398-64AE-4D9F-99F1-529811975C0EQ35076943-F360F257-1724-4D37-9C5A-946075370312Q35167183-E4269A03-2627-4986-B984-E830A82878E1Q35661664-AB987D49-3EBF-4904-984F-58354BE073CBQ35746001-5615461C-5F5A-4412-BC5A-4BB9FACE5E42Q35751615-768D404C-C798-451F-94B7-ED981E699EDFQ35855402-660CA031-167A-4411-8DE3-BA21A88ED98BQ35996924-A0E1D7B9-FB99-4E61-87D2-4B8E86C22033Q36066797-E95FAB53-2620-462A-894F-6251F3B6E3DAQ36076006-ECC7D7E8-4819-4D9B-B9D5-3A8ADB0CA2E6Q36076066-8428DA2C-EC50-4BD3-88F4-9902CDF69C9DQ36095034-0DBC8CA0-8C30-41A1-AB90-66E69CEF2A58Q36150730-C54EB3F7-9495-4974-8FC9-E0F552C14FADQ36181417-646ABBA7-452C-41A7-9C84-109BCB54868FQ36194091-0990EFE0-B34B-49C0-B5C9-A700528D6752Q36304704-49F37BE2-0A98-4772-8F05-07EAFDEA739CQ36816607-2297970D-EA1C-457D-9C74-AB05DF6467D7Q36818945-BF5FC1FE-B84B-498A-BBC1-C30E69AE876EQ36887935-EB74E3B6-B830-4575-B8E2-1857B2767B76Q36913336-EED41833-23CB-43A9-BA08-6CE57AEEB004Q36933393-4E59975C-8B25-42E0-80A0-58C6D67C52B0Q36933469-12004128-5429-4CC9-AE20-6A3C9C0BA336
P2860
Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems.
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Carbapenemase-producing Klebsi ...... s and the role of carbapenems.
@ast
Carbapenemase-producing Klebsi ...... s and the role of carbapenems.
@en
type
label
Carbapenemase-producing Klebsi ...... s and the role of carbapenems.
@ast
Carbapenemase-producing Klebsi ...... s and the role of carbapenems.
@en
prefLabel
Carbapenemase-producing Klebsi ...... s and the role of carbapenems.
@ast
Carbapenemase-producing Klebsi ...... s and the role of carbapenems.
@en
P2093
P2860
P921
P356
P1476
Carbapenemase-producing Klebsi ...... s and the role of carbapenems.
@en
P2093
Antonis Markogiannakis
Athanasios Skoutelis
Athina Argyropoulou
Dimitris Goukos
George L Daikos
Ioanna Stefanou
Ioannis Anyfantis
Leonidas S Tzouvelekis
Martha Nepka
Mina Psichogiou
P2860
P304
P356
10.1128/AAC.02166-13
P407
P577
2014-02-10T00:00:00Z